Lirentelimab

Generic Name: Lirentelimab

Drug Type: Biotech

CAS Number: 2283348-97-8

Unique Ingredient Identifier: SWS48LJU3T

Background: Lirentelimab is under investigation in clinical trial NCT04856891 (A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis).

Clinical Trials

A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria

Phase 2

Terminated

Conditions: Chronic Spontaneous Urticaria

Interventions: Drug: Lirentelimab (AK002)
Other: Placebo

First Posted Date: 2022-09-06

Last Posted Date: 2024-06-06

Lead Sponsor: Allakos Inc.

Target Recruit Count: 127

Registration Number: NCT05528861

Locations: 🇺🇸
Allakos Investigational Site 227-058, Bakersfield, California, United States
🇺🇸
Allakos Investigational Site 227-026, Los Angeles, California, United States
🇵🇱
Allakos Investigational Site 227-302, Łódź, Poland

and more 63 locations

A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis

Phase 2

Terminated

Conditions: Atopic Dermatitis

Interventions: Other: Placebo
Drug: AK002

First Posted Date: 2021-12-13

Last Posted Date: 2024-10-15

Lead Sponsor: Allakos Inc.

Target Recruit Count: 131

Registration Number: NCT05155085

Locations: 🇺🇸
Allakos Investigational Site 218-029, Great Neck, New York, United States
🇺🇸
Allakos Investigational Site 218-048, Sarasota, Florida, United States
🇺🇸
Allakos Investigational Site 218-013, Santa Monica, California, United States

and more 52 locations

A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis

Phase 3

Withdrawn

Conditions: Eosinophilic Gastritis
Eosinophilic Duodenitis

Interventions: Other: Placebo
Drug: AK002

First Posted Date: 2021-12-10

Last Posted Date: 2023-03-03

Lead Sponsor: Allakos Inc.

Registration Number: NCT05152563

Locations: 🇺🇸
Allakos Investigational Site, Seattle, Washington, United States

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis

Phase 3

Completed

Conditions: Eosinophilic Duodenitis
Eosinophilic Gastroenteritis

Interventions: Other: Placebo
Drug: AK002

First Posted Date: 2021-04-23

Last Posted Date: 2024-01-02

Lead Sponsor: Allakos Inc.

Target Recruit Count: 94

Registration Number: NCT04856891

Locations: 🇺🇸
Allakos Investigational Site, Fredericksburg, Virginia, United States

An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

Phase 3

Completed

Conditions: Eosinophilic Duodenitis
Eosinophilic Gastritis

Interventions: Drug: lirentelimab

First Posted Date: 2020-11-09

Last Posted Date: 2024-04-22

Lead Sponsor: Allakos Inc.

Target Recruit Count: 159

Registration Number: NCT04620811

Locations: 🇺🇸
Allakos Investigational Site 216-038, Tustin, California, United States
🇺🇸
Allakos Investigational Site 216-051, Boston, Massachusetts, United States
🇺🇸
Allakos Investigational Site 216-045, Reno, Nevada, United States

and more 35 locations

A Study to Evaluate Safety, Tolerability, and Bioavailability of Subcutaneous Lirentelimab (AK002) in Adult Healthy Volunteers

Phase 1

Completed

Conditions: Study Conducted in Healthy Volunteers

Interventions: Drug: lirentelimab (AK002)
Other: Placebo

First Posted Date: 2020-03-27

Last Posted Date: 2023-04-18

Lead Sponsor: Allakos Inc.

Target Recruit Count: 66

Registration Number: NCT04324268

Locations: 🇺🇸
Allakos Investigational Site, Edgewater, Florida, United States

A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

Phase 3

Completed

Conditions: Eosinophilic Gastritis
Eosinophilic Duodenitis

Interventions: Other: Placebo
Drug: lirentelimab (AK002)

First Posted Date: 2020-03-26

Last Posted Date: 2024-01-02

Lead Sponsor: Allakos Inc.

Target Recruit Count: 181

Registration Number: NCT04322604

Locations: 🇺🇸
Allakos Investigational Site, Spokane, Washington, United States

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis

Phase 2

Completed

Conditions: Eosinophilic Esophagitis

Interventions: Drug: lirentelimab (AK002)
Other: Placebo

First Posted Date: 2020-03-26

Last Posted Date: 2024-01-02

Lead Sponsor: Allakos Inc.

Target Recruit Count: 277

Registration Number: NCT04322708

Locations: 🇳🇱
Allakos Investigational Site, Amsterdam, North Holland, Netherlands

An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis

Phase 2

Completed

Conditions: Eosinophilic Gastritis
Eosinophilic Gastroenteritis
Eosinophilic Duodenitis

Interventions: Drug: AK002

First Posted Date: 2018-09-11

Last Posted Date: 2024-02-28

Lead Sponsor: Allakos Inc.

Target Recruit Count: 58

Registration Number: NCT03664960

Locations: 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸
Cincinnati Children's Hospital, Cincinnati, Ohio, United States
🇺🇸
Vanderbilt University, Nashville, Tennessee, United States

and more 14 locations

A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis

Phase 2

Completed

Conditions: Eosinophilic Gastritis
Eosinophilic Gastroenteritis

Interventions: Other: Placebo
Drug: AK002

First Posted Date: 2018-04-12

Last Posted Date: 2024-01-19

Lead Sponsor: Allakos Inc.

Target Recruit Count: 65

Registration Number: NCT03496571

Locations: 🇺🇸
Ventura Clinical Trials, Ventura, California, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Riverside Clinical Research, Edgewater, Florida, United States

and more 17 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy